Recognition and management of antidepressant discontinuation syndrome
Antidepressant discontinuation syndrome (ADDS) is a new entity in DSM-5 in the category of medication-induced movement disorders and other adverse effects of medication.1 Symptoms generally begin 2–4 days after abrupt discontinuation of anti-depressants taken continuously for at least 1 month.1 ADDS is often seen during taper or after missed doses with short half-life agents, such as paroxetine and venlafaxine.2–4
Up to 70% of patients prescribed antidepressants occasionally skip doses.5 For diagnosis, ADDS symptoms should not be present before dose reduction and should not be better explained by another psychiatric disorder.1 Symptoms that fit the FINISH mnemonic (flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, hyperarousal), can be experienced by up to 40% of patients upon abrupt antidepressant discontinuation.2,6–8 The Discontinuation Emergent Signs and Symptoms Scale (DESS) can be used to quantify symptoms.2 ADDS can also include worsening symptoms of the original illness and can be mistaken for a relapse.1,2 In addition, mis-diagnosing the physical symptoms of ADDS can lead to unnecessary medical and laboratory workup.9
Patients must be informed of ADDS when starting treatment and of the differences between ADDS and withdrawal associated with addiction.10 Although withdrawal symptoms and ADDS could have neurobiological similarities, such as a “receptor rebound” phenomenon upon sudden discontinuation,2,7,11,12 there are important differences. Unlike antidepressants, use of drugs of abuse include reinforcing/euphoric effects of the drug and associated drug-seeking behaviour.1 Symptoms of ADDS are associated with short half-life agents, and symptoms are usually mild and short-lived.1
Risk for ADDS is highest with short half-life agents, high doses and rapid taper.1,10 The risk also appears to be higher for those who have taken anti-depressants for 8 weeks or longer,13 experience anxiety symptoms when starting a selective serotonin reuptake inhibitor (SSRI), are taking other centrally acting medications (e.g., anti-psychotics, antihypertensives, antihistamines), are children/adolescents, or have a history of ADDS episodes.2,10 ADDS has been reported with all monoamine oxidase inhibitors (MAOIs) and commonly presents with agitation, movement disorders, and sleep and speech problems.10 ADDS has most commonly been reported for amitriptyline and imipramine among tricyclic antidepressants (TCAs) and paroxetine and venlafaxine among SSRIs.10 Neonatal venlafaxine discontinuation syndrome upon maternal venlafaxine discontinuation before childbirth has been reported.14 ADDS with TCAs and SSRIs commonly presents with flu-like symptoms, insomnia and vivid dreams, and with additional “shock-like” sensations with SSRIs.10 Movement disorders have occasionally been reported with both TCAs and SSRIs.10 Symptoms of ADDS have not been reported with abrupt discontinuation of agomelatine10,15,16 or vortioxetine.10,17
Prevention of ADDS, particularly for short half-life agents, includes a gradual discontinuation over 4 weeks with a slow rate of taper at the end,2,6,7 and a longer taper for those on MAOIs. Importantly, patients need reassurance that ADDS is common, self-limited and often mild.2 If symptoms are severe, restarting the original antidepressant or another antidepressant with a long half-life in the same class can be followed by gradual taper.2 When ADDS symptoms persist despite slow taper,18 abrupt withdrawal options could be considered, particularly when patients prefer a short period of intense symptoms to a longer period of mild symptoms associated with a gradual taper.